Search

Displaying results 4281 - 4290 of 10000 in total
  1. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  2. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  3. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  4. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    It is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

  5. Drug

    Nifuroxazide

    go.drugbank.com/drugs/DB13855
    Investigational

    Mixtures: METRONIDAZOL/NIFUROXAZIDA 300 MG/100 MG., METARSAL N CAPSULASProducts: GASTIL 200 MG, NIRABEN CAPSULE 200 mg
  6. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  7. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

  8. Drug

    Sulfisoxazole

    go.drugbank.com/drugs/DB00263
    ApprovedVet approved

    A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.

    Synonyms: N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide, 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide
  9. Drug

    Cefepime

    go.drugbank.com/drugs/DB01413
    ApprovedInvestigational

    Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. … [A249050] The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the

    Synonyms: (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylateProducts: POZINEG® 1000 MG
  10. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.